The historical data trend for Royalty Pharma's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Royalty Pharma Annual Data
Trend
2020-12
2021-12
2022-12
2023-12
2024-04
Forward PE Ratio
18.25
12.24
10.19
6.87
8.31
Royalty Pharma Quarterly Data
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
Forward PE Ratio
14.56
18.25
16.03
15.97
14.47
12.24
11.79
14.66
10.92
10.19
9.02
7.61
6.20
6.87
8.94
Competitive Comparison
For the Biotechnology subindustry, Royalty Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Forward PE Ratio Distribution
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Forward PE Ratio falls into.
Royalty Pharma Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Royalty Pharma (NAS:RPRX) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Royalty Pharma Forward PE Ratio Related Terms
Thank you for viewing the detailed overview of Royalty Pharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Royalty Pharma (Royalty Pharma) Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RPRX has been successfully added to your